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Myths Surrounding Covid-19 




The Covid-19 pandemic has propelled public health officials into the  
socio-political sphere due to the need for constantly updated information on behalf 
of the public. However, many individuals choose to acquire health information/
guidance from indirect sources, including social media, news organizations, and 
general word of mouth. As a result, myths and false narratives about various 
essential health topics, including vaccine characteristics and protective measures, 
can circulate un-verified between millions of individuals with little recourse. These 
can further widen the “gap” between public knowledge and current research, 
resulting in lower vaccine uptake (vaccine hesitancy) and protective measure 
adherence. Such actions have profound implications as nations attempt to achieve 
herd immunity and end the pandemic once and for all. Thus, it is vital that public 
health officials, health providers, researchers, and the general public be able to 
differentiate common Covid-19 myths from facts and be prepared to approach such 
interactions via sound reasoning and research-based evidence. This chapter will 
serve as a guide to accomplish just that.
Keywords: Covid-19 vaccine, vaccine hesitancy, herd immunity, myths, mRNA 
technology, clinical trial
1. Introduction
Before the Covid-19 pandemic, vaccine hesitancy was a term reserved for indi-
viduals, primarily in developed countries, in which there is a significant refusal or 
delay in uptake despite vaccine availability/access. In this instance, the term minute 
might be misleading since vaccine hesitancy is in no way a monolith. Indeed, vac-
cine hesitancy can take many forms and stems from multiple etiologies. However, 
never in the past decade had individuals’ choices and personal convictions regard-
ing a vaccine had such a profound effect on the perceived ability of entire nations to 
effectively control a pandemic at large [1].
This “rise to fame” and increased recognition in the public health community 
was borne out of the realization that multiple vaccine candidates were nearing the 
later stages of clinical trials in the fall of 2020. After nearly nine months of social 
protective measures and economic turmoil, a clear disparity had been recognized 
between the rapid vaccine production process and public knowledge/acceptance 
toward eventual vaccine uptake. For instance, the first vaccine (Pfizer) against 
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Covid-19 was given emergency use authorization on December 11, 2020, in the U.S. 
A week later, a second vaccine (by Moderna) was also approved. However, unlike 
traditional vaccine rollouts, the U.S. government had pre-purchased hundreds of 
millions of doses from multiple manufacturers via Operation Warp Speed, hoping 
to speed up the initial delivery to essential frontline workers and high-risk individu-
als [2]. The program was considered an overnight success as over 6 million doses 
of each vaccine was shipped within a week of authorization, enough to vaccinate 
the entire U.S. healthcare worker population. Within a few weeks, reports began 
emerging that only 68% of healthcare workers, the supposed most informed subset 
of the population, had chosen to receive the vaccine when offered to them [3]. To 
put this in perspective, annual influenza vaccine uptake in the U.S. stands at around 
81% [4]. One might ask, what separates the two numbers? The answer is, of course, 
much deeper than surface level; however, one question has been proposed and 
proven highly appropriate in post-roll out public opinion polling: where was the 
vaccine marketing campaign? After all, the U.S. spent over $12 billion on vaccine 
candidates undergoing clinical trials before a single jab was given [2]. The first offi-
cial Covid-19 vaccination information campaign was not announced until January 
Figure 1. 
“COVID-19 vaccine acceptance rates worldwide. For countries with more than one survey study, the vaccine 
acceptance rate of the latest survey was used in this graph. The estimates were also based on studies from 
the general population, except in the following cases where no studies from the general public were found 
(Australia: parents/guardians; DRC: healthcare workers; Hong Kong: healthcare workers; Malta: healthcare 
workers).” Source: Reproduced from “Figure 2: COVID-19 vaccine hesitancy worldwide: A concise systematic 
review of vaccine acceptance rates” by Malik Sallam. Licensee MDPI, Basel, Switzerland. Made available 
under the CC by 4.0 license.
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27, 2021, over a month after the first vaccine approval. Multiple analyses of the U.S. 
vaccine timeline have dubbed this period, between the late summer of 2020 and 
early spring of 2021, the “lost time” in the fight against the Covid-19 pandemic [5].
Thus, a question emerges. What could have been done to quell the impend-
ing rise of vaccine-hesitant individuals (Figure 1)? Here we find a great model in 
annual influenza immunization campaigns. The initiatives are backed by decades 
of research showing that a multi-disciplinary collaboration consisting of provid-
ers, public agencies, and private sector companies is needed to adequately address 
questions and instill confidence in individuals regarding upcoming vaccines. The 
word upcoming is critical in this context, as the marketing campaign is kicked off 
months BEFORE the first jab is expected to be given. Consequently, a logical time to 
begin educating individuals on the developing Covid-19 vaccines likely would have 
been months before the first approval. Unfortunately, the movement did not catch 
enough support, and we may never know the difference this may have made on 
vaccine hesitancy levels during the rollout.
During this “lost time,” as mentioned, very little data exists surrounding vaccine 
hesitancy levels via traditional cross-sectional studies/surveys. Most statistics cited 
are taken from public opinion polling, which asked individuals their opinion on 
various aspects of the pandemic and, specifically, whether they intended to receive 
a Covid-19 vaccine if and when it is approved. To continue with the U.S. example, 
a poll taken in July 2020 showed that only 42% of Americans were considering 
getting vaccinated, with lower rates among minority groups, who are dispropor-
tionately affected by Covid-19 in both hospitalization and mortality rates [6]. Fast 
forward to November, and that number had not changed. However, the percent-
age of anticipated uptake among Black Americans had gone down [7]. Hence, we 
have our disparity: billions of dollars and public resources were given to vaccine 
Figure 2. 
Traditional vs. (accelerated) Covid-19 vaccine development timeline. Source: GAO analysis of Food and Drug 
Administration (FDA), pharmaceutical research and manufacturers of America, and Operation Warp speed 
information. | GAO-21-319.
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development, while virtually no attention was given to promoting the vaccine 
among its intended populations.
But what could have caused this? How did millions of individuals in one of the 
most developed nations in the world with access to social media, news outlets, and 
governmental information not warm to the greatest vaccine development feat in 
modern history? Well, aside from the missing vaccine marketing campaign, other 
factors must have been at play to erode public confidence and stall optimism in 
the wake of the surging pandemic. Of these factors, one was very preventable and 
remains a global barrier to vaccine administration: myths. That is, myths surround-
ing virtually every aspect of vaccine production, trials, administration, and long-
lasting effects. Such myths, circulated at large with the rise of unverified outlets 
(e.g., social media), have the ability to reach a mass audience with little recourse. A 
potent example lies in the fact that one false statement from a well-known celebrity 
can potentially reach hundreds of millions of viewers before any official rebuttal 
or correction is offered. Therein lies the challenge in combatting myths, reliant 
on the public’s level of trust in public health officials compared to those spouting 
such research-lacking claims [8]. To accomplish this on an individual level, like all 
delicate encounters, requires both first-hand knowledge and effective communica-
tion techniques. While the latter two are character traits that may or may not be 
improved (see Section 2), the first is an area that deserves a review.
2. Addressing vaccine myths
Before diving in, it is worth reiterating that countering vaccine hesitancy, 
similar to the definition itself, is not a one-size-fits-all approach. The knowledge 
laid out below will provide a foundation for providers and the general public alike 
to interact with and have fruitful conversations regarding common misconceptions. 
However, there are extraneous principles that are important and necessary to follow 
to maximize such opportunities. A 2018 study out of the Thomas J. Long School 
of Pharmacy and Health Sciences identified several successful strategies that can 
be used to improve confidence and decrease hesitancy levels in recipients. Even 
more impressive is that the study involved pharmacy students rather than licensed 
medical providers, decreasing the likely power differential and knowledge gap seen 
in clinical practice [9].
The first viable strategy found was that of rapport. For example, a commonplace 
argument for vaccine aversion is that “vaccine side effects are worse than the disease 
itself.” Instead of trying to ramble off a dozen facts and figures, a better solution 
was found in asking patients to boil the fear down to a specific side effect (e.g., 
headaches, diarrhea, etc.). Once this was done, the student could dig even deeper to 
determine if the patient had personally suffered or had a family history of suffering 
from such symptoms. From here, rapport could be established, and a risk–benefit 
analysis consisting of actual data would be much more appropriate than trying to 
combat the entire notion that vaccines should be “side-effect free.” Now, this may 
seem like a “no brainer.” However, one may not know as much as they think about 
their friend’s/family member’s health if they only interact once a year. Thus, it may 
be wise to take a deeper dive, regardless of relationship, before countering their 
pre-existing vaccine perceptions.
Once rapport has been established, a winning strategy is to start with the posi-
tives rather than harping on rare side effects and complications. A popular starting 
point would be explaining vaccine-driven herd immunity and how community 
protection is the basis for eradication/control of nearly all major outbreaks. Next, 
a solid turning point would be to suggest that they resist looking to unqualified 
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personnel (on social media, television, etc.) and talk to an actual expert on the 
topic, such as their physician or pharmacist. Another important goal is to evalu-
ate an individual’s level of knowledge about the vaccine. Studies have shown that 
greater education simply about the vaccine itself and how it works can lower levels 
of hesitancy [10]. Thus, they do not need to walk away agreeing with you; simply 
informing them about how the vaccine works (mRNA technology, viral vector, 
etc.) is a step forward in our book. Then, it is important to assess their current 
risk–benefit stage. Two popular dimensions used are an individuals’ perceived 
likelihood of harm and perceived consequence severity if that harm were to occur 
[11]. Narrowing this down, similar to establishing rapport, is key to addressing 
underlying fears/aversions. Consequently, it is also important to establish their 
“best-case scenario.” They likely want the same endpoint for society (eradication/
negligible transmission). Using this as common ground and talking about realistic 
paths toward getting there is an excellent segway into discussing current research 
projections.
Two factors that cannot be ignored are that of socio-cultural pressure and 
religious convictions. Unfortunately, these are very hard to change in the long-
term, much less in the course of a single conversation. Leveraging the idea of social 
responsibility, where an individual has a sort of role to play in achieving herd 
immunity for the betterment of those around them, has proven effective. However, 
a fine line should not be crossed so as to force down a specific belief on individual 
behavior [12].
These research-driven strategies may or may not be enough to build your com-
munication arsenal the next time a patient, friend, or loved one mentions hesitancy 
toward vaccination. However, striving for rapport, providing judgment-free edu-
cational information, and being knowledgeable about all components of vaccine 
development and administration is a recipe for success in this fight toward ending 
the Covid-19 pandemic and future pandemics to follow. Speaking of knowledge, 
perhaps you are wondering what myths exactly are circulating about Covid-19 
vaccines. If so, let us address your eagerness (not hesitancy).
3. High-yield vaccine myths to know
Recent studies have identified five common myths surrounding Covid-19 vaccines 
[13, 14]. Let us break them down one by one, separating fact from fiction.
3.1 Myth #1: getting the Covid-19 vaccine will give you Covid-19
To date, no vaccine authorized or in development in the U.S. contains the live 
SARS-CoV-2 virus. Thus, receiving a Covid-19 vaccine cannot and will not cause 
Covid-19 infection. However, symptoms seen in common viral infections can arise 
due to the body’s immune response to the vaccine’s mechanism of action. Symptom 
presentation and timelines can vary among different vaccine types and recipient 
demographics. Generally, the most common symptoms seen in Covid-19 vaccinated 
individuals are injection site pain, fever, muscle pain, fatigue, and/or headaches. 
These are a completely normal and benign response as the immune system detects 
the vaccine components and begins adapting to fight off an actual Covid-19 infec-
tion, should that individual get exposed. These side effects typically occur within 
24–48 hours post-vaccination. Experts often refer to this as a “good sign” that your 
immune system is building a response to battle future infections. While this period 
generally contains a mild presentation, there are steps you can take to alleviate side 
effects that arise. The first is to use an ice pack or damp cloth to reduce injection 
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site pain/soreness. Next is to take an over the counter (OTC) pain reliever such as 
acetaminophen. Finally, finding ways to de-stress (e.g., taking off of work, self-care 
routine) is always a good idea to strengthen your immune system [15].
3.2 Myth #2: vaccine development was rushed and unreliable
In this instance, it is helpful to begin by confirming one of the assumptions of 
this myth: that the Covid-19 vaccine was developed in record time [16]. Yes, there is 
some merit to this assumption. However, the other two assumptions are where this 
myth fails to hold water: that corners were cut, and safety was inherently not ensured 
as in traditional vaccine development/supervision. There are two possibilities in this 
discussion that are important to recognize before diving in: (1) the individual holds 
this distrust regarding all vaccines (or at least the idea is not confined to the Covid-
19 vaccine development) or (2) the individual solely holds this belief surrounding 
Covid-19 vaccine production. If the former, then the individual needs to be coun-
seled about basic vaccine development facts as a whole. If the second is the case, then 
the argument becomes much more straightforward: how did/does Covid-19 vaccine 
development compare to previous vaccines? For this, we can look to historical data 
and the “usual” timeline, step by step (Figure 2). So how exactly are vaccines made?
3.2.1 Discovery (1-5 years)
The discovery phase generally consists of learning all aspects of the microbe 
we are trying to combat (e.g., structure, mechanism of action, etc.) Once SARS-
CoV-2 was identified as a type of coronavirus, researchers were able to sequence its 
genome. From here, the spike protein was selected as a unique target based on its 
function allowing the virus to penetrate host cells and cause infection. Additionally, 
the spike protein had been targeted before against the Middle East respiratory 
syndrome (MERS) coronavirus. This precedent allowed the discovery phase to be 
accelerated to weeks or months rather than years.
3.2.2 Preclinical (2-4 years)
The preclinical stage generally consists of sifting through potential antigens 
(such as the spike protein) and deciding which will produce the best immune 
response and long-lasting protection. This is determined by assessing the safety 
of candidates for each antigen in cell and tissue cultures as well as in live animal 
testing. Traditionally, studies are performed on rats and mice; however, the rise 
of transgenic “humanized” mice, genetically modified with human genetic com-
ponents, has aided in generalization toward human bodily responses. Researchers 
must also determine appropriate dosing and delivery form (e.g., injection, pill, 
etc.). Once this has been completed, the candidate vaccine moves on to the clinical 
stages. And how did this notoriously tedious process happen so quickly in the case 
of Covid-19? One example was found in March 2020, when Janssen reported that 
their novel technology platform, used in its Ebola and novel RSV and HIV viral 
vector vaccines, was effective against Covid-19. Thus, decades of research on the 
platform’s delivery mechanism, ideal thresholds, and animal study proof-of-concept 
were utilized to jumpstart the development timeline.
3.2.3 Phase I clinical trial (1-2 years)
The main goal of a Phase I trial is to show that the vaccine is safe in humans and 
how the body receives it. A small group of volunteers is enrolled. Careful attention 
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is given to signs of adverse events, such as toxicity, organ damage, and death. After 
the trial is completed, data is analyzed and submitted to the FDA for approval to 
begin Phase II trials. The FDA has the ability at any point to intervene if one or more 
serious adverse events are found. If a treatment has already been shown to work for 
a different condition, the Phase I trial can be shortened or accelerated to Phase II 
since the vaccine has proven safe in human patients. As was the case with Covid-19, 
multiple manufacturers were able to combine Phase I and Phase II trials since the 
steps can be done in parallel without compromising oversight. The experience with 
the delivery system used for Ebola in Janssen’s case is a key example.
3.2.4 Phase II clinical trial (2 years)
Phase II trials primarily focus on narrowing down the ideal dosage to maximize 
effectiveness and limit side effects. A larger patient population is used. Patients are 
assigned to multiple groups with varying doses, delivery methods, or controls to 
compare outcomes. All treatments given have been previously tested (including pla-
cebo or current vaccine standard), and this step is meant to pick a “best” scenario. 
When the trial concludes, the results of each group are compared to determine if 
the vaccine is better than current treatment/vaccine resources and, if so, ideal dos-
ing/delivery. This is a major checkpoint whereby the FDA can either discontinue the 
study due to adverse events/ineffectiveness or push it through to Phase III trials.
3.2.5 Phase III clinical trial (2-3 years)
The main hallmark of a Phase III trial is its size, typically around 3,000 par-
ticipants. Enrolling this many patients with a disease can be a drawn-out process 
depending on disease prevalence and geographical distribution, often lasting 
several years. Perhaps the most remarkable feat of the Covid-19 clinical trial race 
was the ability of vaccine studies to enroll record numbers of patients in record 
time. Take, for instance, the Pfizer Phase III trial, which recruited over 43,000 
participants in just four months. This magnificent accomplishment was able to both 
shave off precious time and instill greater confidence in the public and scientific 
community due to the sheer sample size. After all, the number of participants was 
over ten times greater than that of a typical vaccine candidate. One might argue 
that this was an invaluable marketing strategy given the shortened development 
timeline. While this is likely true, it is important to realize that corners were not cut 
in enrolling patients either. On the contrary, pharmaceutical manufacturers worked 
with epidemiologists to ensure that the patient population recruited for the studies 
was representative of the target population for vaccine administration. In layman’s 
terms, groups that are typically hard to reach in general studies (e.g., underserved 
groups, those at highest risk of transmission) were given priority in enrollment 
efforts. Once all trial data is compiled, a New Drug Application (NDA) is filed with 
the FDA, asking for consideration to bring the vaccine to market.
3.2.6 FDA approval/review (1 year)
One cannot understate the amount of administrative burden and patience that 
goes into reaching this point, much less achieving FDA authorization. A common 
question asked by patients after witnessing the Covid-19 spectacle is, “Why can’t we 
approve everything this fast?” An excellent question, indeed, given the abundance 
of vaccines needed for incurable diseases. To answer this, let us talk about what goes 
into the FDA’s decision once an NDA hits its desk. The first component a manu-
facturer must prove is that the vaccine is safe and effective throughout all clinical 
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trial data. From here, the decision moves toward logistics. Is there a manufactur-
ing process in place? Can this process consistently meet the needs of the general 
public? Are the batches equivalent to clinical trial data in terms of effectiveness and 
safety? If all of these boxes are checked, then approval is a possibility. Several panels 
meet to consider the vaccine data submitted for approval and licensure/regulation 
grants. The reason for the year timeline is based on a variety of factors. First, a large 
percentage of applications are incomplete, with required studies missing. Next, 
a candidate is put on a priority ranking list in which drugs are reviewed based on 
global need. Then, the FDA must meet with sponsors to ensure no corners were cut 
and that transparency was insured. Finally, an in-depth manufacturing analysis 
must be conducted to ensure that the vaccine distribution can meet the global needs 
of world populations (especially underserved and at-risk groups).
As another wonder of Covid-19 vaccine development, two decisions were 
made that cut the necessary FDA review period down to less than three weeks: 
parallel review and anticipatory manufacturing. Since the Covid-19 pandemic was 
logically considered priority #1, all possible resources were given to evaluate and 
approve/reject clinical trial data upon submission. Additionally, trial transparency 
and adverse reaction monitoring was performed concurrently to ensure proper 
oversight. These cut the typical six-month to one-year delay off of the majority 
of pre-NDA phases. Anticipatory manufacturing, the production of unapproved 
vaccines in anticipation of approval, was a previously unproven idea that investing 
in potential candidates would be cost-effective in the long run and shave previous 
months or even years off the vaccine distribution timeline. Consequentially, this 
could save millions of lives by slowing the pandemic morbidity and mortality. This 
gamble has proven largely successful in the early months of vaccine rollout, and 
specific examples can be found under the “Introduction.”
3.2.7 Manufacturing (6 months-3 years)
As mentioned, anticipatory manufacturing was the key to jumpstarting the vac-
cine production timeline. Currently, AstraZeneca/Oxford is producing an astound-
ing 200 million doses of their Covid-19 vaccine per month. To give perspective, 
during the H1N1 outbreak, AstraZeneca was able to produce only 17 million doses 
of their H1N1 vaccine. That represents a roughly twelve-time increase in production 
compared to the previous pandemic [17]. While this is not a perfect comparison 
given differing circumstances, it is both probable and likely that the jumpstart in 
production and massive funding overhauls contributed to maximizing vaccine 
production.
3.2.8 Phase IV clinical trial (optional)
Phase IV trials are studies of adverse serious events and safety hazards that arise 
once a vaccine is approved and made available on the market. The FDA carefully 
monitors such instances through MedWatch, a service allowing providers, patients, 
and the trial sponsor to report a suspicious event. At any point, additional Phase IV 
trials may be commissioned by the FDA or sponsor to examine vaccine effects for 
varying benefits, risks, and patient populations [18].
3.3  Myth #3: the only way to reach herd immunity and end the pandemic is by 
letting the virus spread
Herd immunity has risen to prominence in both the scientific community and 
the general public due to its unique role in infectious disease outbreaks. To set the 
9
Myths Surrounding Covid-19 Vaccine Candidates: A Guide to Fight Back
DOI: http://dx.doi.org/10.5772/intechopen.98714
record straight, herd immunity is the only proven method of definitively prevent-
ing the spread of infectious diseases to the point of being statistically irrelevant. 
This is achieved by a large percentage of the population, called the herd immunity 
threshold, being protected from infection (Figure 3). Consequently, the unpro-
tected (e.g., uninfected individuals, individuals who cannot or choose not to get 
vaccinated) also become protected due to the interrupted transmission chain. This 
part, in most cases, is largely understood. Where the record gets bent is in HOW 
herd immunity is reached. It is important to understand that there are two routes by 
which herd immunity can be achieved: natural infection and vaccines [19].
3.3.1 Natural infection
When enough individuals in the population have recovered from a specific dis-
ease and developed lasting antibodies against future infection, herd immunity can 
theoretically be reached. However, the issue with this myth’s underlying assumption 
is that relying on natural infection alone ignores two common deviants: reinfection 
and health toll.
While admittedly, the evidence for reinfection risk is limited given the novel 
nature of the pandemic, there have been clear instances of Covid-19 reinfection in 
the community. This phenomenon is dependent on an individual’s antibody levels 
and appears to heighten in risk between six months to a year. Significant reinfection 
incidence can substantially harp a community’s progression toward herd immunity 
due to waning antibody responses.
While a community could theoretically remove all protective measures and 
allow the disease to run rampant until herd immunity is achieved, this would allow 
the full brunt of the disease to affect the community. In layman’s terms, this means 
that millions of individuals could suffer and potentially die unnecessarily. In July 
2020, experts predicted that approximately 70% of the U.S. population would need 
to recover from Covid-19 infection to slow disease spread. Underlying this number 
was the reality that more than five million individuals could perish before this feat 
was achieved. As you can probably guess, such a situation is unacceptable, and 
hence social protective measures were mandated/strongly encouraged until vac-
cines could fill their role in ending the pandemic [20].
3.3.2 Vaccines
As mentioned, a strong antibody response against the target disease is key to 
achieving herd immunity. Vaccines remain the quickest and most efficient way of 
promoting antibody responses on a mass scale. Unlike natural infection, vaccine-
driven immunity does not require illness to achieve protection. Herd immunity has 
been successfully reached against contagious diseases, including rubella, polio, 
smallpox, diphtheria, and many more. In the long run, vaccines offer a great way 
to protect newborns and immunocompromised individuals from disease without 
suffering from the disease itself. While vaccine-driven immunity is the gold stan-
dard in fighting back against pandemics such as the Covid-19 pandemic, it is not 
without faults. Several barriers remain in the fight against Covid-19 that need to be 
solved before the world can declare victory. First, vaccine hesitancy, as we hashed 
out in detail before, is a predominant risk to vaccine uptake. If individuals choose 
not to get vaccinated, herd immunity becomes much harder to reach. Please see 
“Introduction” for more details. Next is the issue of protection duration. While 
preliminary studies have shown adequate antibody levels for at least six months 
post-infection, the exact antibody level drop-off timeline is unknown. Thus, 
protection from vaccination may be insufficient and require a “booster” dose down 
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the road. Additionally, new variants of the Covid-19 virus may be less efficiently 
targeted by the existing vaccines and require uptake of new vaccines specially made 
to counter such variants. Finally, outbreak control, while traditionally thought of 
on a community level, relies on limited transmission in surrounding regions as well. 
Thus, uneven vaccine distribution and resulting low transmission rates around an 
area can impact the ability of that area to contain the virus assuming individuals 
travel to and from [21].
Figure 3. 
“The top box shows an outbreak in a community in which a few people are infected (shown in red) and the rest 
are healthy but unimmunized (shown in blue); the illness spreads freely through the population. The middle 
box shows a population where a small number have been immunized (shown in yellow); those not immunized 
become infected while those immunized do not. In the bottom box, a large proportion of the population have 
been immunized; this prevents the illness from spreading significantly, including to unimmunized people. In the 
first two examples, most healthy unimmunized people become infected, whereas in the bottom example only 
one fourth of the healthy unimmunized people become infected.” Source: Reproduced from Tkarcher under the 
creative commons attribution-share alike 4.0 international license.
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3.4 Myth #4: mRNA technology is brand new
Perhaps the easiest myth to explain, let us state the historical fact: mRNA technol-
ogy is not new, much less to fighting a pandemic. In fact, mRNA technology was pur-
sued in vaccine research for quick response to a novel pathogen, such as Covid-19. The 
first studies using mRNA technology were in the 1990s. At the time, experts widely 
recognized that conventional vaccine types (e.g., live attenuated, subunit, etc.) were 
not always sufficient to combat pathogens capable of evading the adaptive immune 
response. Additionally, development and large-scale deployment were obstacles in 
the face of pandemic-speed response. Early reports showed that the introduction of 
mRNA could stimulate protein production and therefore antibody production via a 
disease-specific immune response. While early trials did hit roadblocks due to toxicity 
and delivery failures, recent advances such as RNA carriers and synthetic delivery have 
made mRNA engineering much more efficient. Before the Covid-19 pandemic, mRNA 
technology had been used in vaccine trials for cancer and other diseases for over a 
decade. However, the Covid-19 vaccines by Moderna and Pfizer/BioNTech are the first 
mRNA vaccines to receive FDA emergency use authorization. The crucial point here is 
that the technology is not experimental, has been excruciatingly vetted (see Myth #2), 
and will likely be a mainstay in vaccine development for future pandemics [22].
Figure 4. 
A diagram showing the mechanism by which various Covid-19 vaccines/vaccine candidates induce an immune 
response. Source: Reproduced from Gavi https://www.gavi.org/vaccineswork/there-are-four-types-covid-19-
vaccines-heres-how-they-work under creative commons attribution 2.0. Licensee the Wellcome Trust: https://
wellcome.org/.
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3.5 Myth #5: Covid-19 vaccines can alter your DNA
This is a common misconception, likely stemming from the fact that certain 
vaccines utilize parts of viruses/bacterium as a vector or stimulus to jumpstart the 
immune system [23]. To give context, we first need to explain the different types of 
vaccines in use/development against Covid-19 (Figure 4).
3.5.1 mRNA
The Pfizer/BioNTech and Moderna Covid-19 vaccines utilize mRNA technology. 
mRNA is a messenger bridge between DNA and protein synthesis. This process is of 
high relevance since Covid-19 virus surface proteins, particularly the spike protein, 
were identified early on. Thus, genetically engineered mRNA can be produced 
capable of instructing one’s cells to make a partial piece of the spike protein that is 
completely harmless. By introducing raised levels of the spike protein fragments, 
the immune system will respond by making antibodies to the foreign particles. 
Upon infection with Covid-19, the body will have a large supply of antibodies ready 
to crush the virus. While the mRNA does influence body cells to produce protein 
fragments, it is rapidly degraded and does not enter the cells or influence DNA 
components [22].
3.5.2 Protein subunit
The Novavax vaccine is classified as a protein subunit vaccine. In this method, 
segments of a virus known to trigger the immune system are carefully selected. In 
the case of Covid-19, the vaccine consists of harmless spike proteins (cf. mRNA 
to stimulate spike protein production in mRNA vaccines). Once introduced, the 
immune system will recognize the spike proteins and mount an immune response. 
This will result in antibody formation, creating a reserve if that individual becomes 
infected. There is no effect on an individual’s DNA [24].
3.5.3 Vector
The Janssen/Johnson & Johnson and AstraZeneca/University of Oxford Covid-
19 vaccines utilize a vector-driven approach. This means that genetic material 
from SARS-CoV-2, the virus that causes Covid-19, is inserted into a live, weakened 
virus such as an adenovirus. The adenovirus serves as a delivery mechanism, 
allowing the genetic material to instruct your body’s cells to make copies of certain 
proteins. These proteins are pre-selected based on their ability to stimulate the 
immune system to make antibodies and white blood cells. Consequently, if an indi-
vidual is then infected with that specific virus (Covid-19), the immune system will 
be in an excellent position to fight back via rapid antibody production. Individuals 
who receive a Covid-19 vector vaccine cannot become infected with Covid-19 or 
the vector virus used as a direct result of vaccination. Additionally, the genetic 
material inserted does not integrate or become part of an individual’s DNA in any 
way [25].
3.5.4 All vaccine types
In summary, none of the vaccines currently used against Covid-19 have the abil-
ity to alter an individual’s DNA. Therefore, any such claim is a gross misrepresenta-
tion of both molecular processes and modern vaccine technology.
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4. Conclusion
The Covid-19 pandemic has brought vaccine hesitancy to the forefront of both 
public conversation and health marketing research. While global vaccine develop-
ment succeeded in launching several candidates against Covid-19, the missing 
link in such race was arguably a collaborative, targeted immunization campaign to 
inform and raise optimism toward the coming vaccines [2]. As a result, precious 
months were lost during a pandemic in which over three million lives have been 
lost [26]. Now, a few months after the initial vaccine rollout, nations are facing a 
declining yet formidable cohort of individuals who remain skeptical and/or averse 
to vaccine uptake due to a variety of factors [7]. This poses a serious challenge to 
communities attempting to reach herd immunity and crush the pandemic once and 
for all. Healthcare providers enjoy a unique position in society, capable of swaying 
public opinion through both direct and indirect interactions. Additionally, busi-
nesses, religious organizations, and loved ones represent promising avenues of 
outreach that should be empowered to combat vaccine hesitancy in their respective 
spheres [2]. While communication setting, skills, and personal relationship all play 
a role in one’s ability to “fight back” against hesitancy, knowledge has a direct corre-
lation with success in this endeavor. Thus, recognizing common myths surrounding 
Covid-19 vaccine candidate development, production, and administration is key to 
having fruitful discussions capable of persuading individuals to reconsider vaccina-
tion [9]. Herd immunity is closer than ever; it is up to us to band together and defeat 
misconceptions with research-backed knowledge, humility, and understanding. 
Together, we can and will crush the Covid-19 pandemic and any that dare to follow.
Acknowledgements
The author thanks Ms. Kathryn Wells for invaluable feedback regarding earlier 
drafts of this manuscript. The author is also grateful to the original authors of the 
various figures reproduced under their respective licenses.
Conflict of interest
The author declares no conflict of interest.
Notes/Thanks/Other declarations
Research surrounding the Covid-19 vaccine candidates, vaccine hesitancy 
response, and public optimism is fast-changing. All data used and studies cited 
were current at the time of this writing. For up-to-date information, please visit the 
World Health Organization and/or Centers for Disease Control and Prevention.




University of Miami Miller School of Medicine, Miami, FL, USA
*Address all correspondence to: jjz41@med.miami.edu
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Myths Surrounding Covid-19 Vaccine Candidates: A Guide to Fight Back
DOI: http://dx.doi.org/10.5772/intechopen.98714
References
[1] MacDonald NE, Hesitancy  
SWGoV. Vaccine hesitancy: Definition, 
scope and determinants. Vaccine. 
2015;33(34):4161-4164. doi: 10.1016/j.
vaccine.2015.04.036.
[2] Zizzo J. The Missing Link in the 
Covid-19 Vaccine Race. Hum Vaccin 
Immunother. 2021;17(5):1326-1328. doi: 
10.1080/21645515.2020.1831859.
[3] Prevention CfDCa. About COVID-19 
Vaccine Delivered and Administration 
Data. In: Diseases DoV, editor. cdc.gov: 
U.S. Department of Health & Human 
Services; 2021.
[4] Kelly DA, Macey DJ, Mak DB. 
Annual influenza vaccination. Hum 
Vaccin Immunother. 2014;10(7):1930-
1934. doi: 10.4161/hv.29071.
[5] Dror AA, Eisenbach N, Taiber S, 
Morozov NG, Mizrachi M, Zigron A,  
et al. Vaccine hesitancy: the next 
challenge in the fight against COVID-19. 
Eur J Epidemiol. 2020;35(8):775-779. 
doi: 10.1007/s10654-020-00671-y.
[6] YouGov. Yahoo! News Coronavirus -  
July 30. 2020.
[7] YouGov. Yahoo! News Presidential 
Election - October 26. 2020.
[8] De Vito EL. [Eight persistent  
COVID-19 myths and why some people 
still believe them]. Medicina (B Aires). 
2020;80 Suppl 6:112-6.
[9] Vyas D, Galal SM, Rogan EL, 
Boyce EG. Training Students to Address 
Vaccine Hesitancy and/or Refusal. Am J 
Pharm Educ. 2018;82(8):6338. doi: 
10.5688/ajpe6338.
[10] Jarrett C, Wilson R, O'Leary M, 
Eckersberger E, Larson HJ, Hesitancy 
SWGoV. Strategies for addressing 
vaccine hesitancy - A systematic review. 
Vaccine. 2015;33(34):4180-4190. doi: 
10.1016/j.vaccine.2015.04.040.
[11] Dubé E, Laberge C, Guay M, 
Bramadat P, Roy R, Bettinger J. Vaccine 
hesitancy: an overview. Hum Vaccin 
Immunother. 2013;9(8):1763-1773. doi: 
10.4161/hv.24657.
[12] Koslap-Petraco M. Vaccine 
hesitancy: Not a new phenomenon, but 
a new threat. J Am Assoc Nurse Pract. 
2019;31(11):624-626. doi: 10.1097/
JXX.0000000000000342.
[13] Organization WH. Coronavirus 
disease (COVID-19) advice for the 
public. Mythbusters2021.
[14] Prevention CfDCa. Myths and Facts 
about COVID-19 Vaccines. In: Diseases 
DoV, editor.: U.S. Department of Health 
& Human Services; 2021.
[15] Izda V, Jeffries MA, Sawalha AH. 
COVID-19: A review of therapeutic 
strategies and vaccine candidates. Clin 
Immunol. 2021;222:108634. doi: 
10.1016/j.clim.2020.108634.
[16] Office USGA. OPERATION WARP 
SPEED. 2021.
[17] Sparrow E, Wood JG, Chadwick C, 
Newall AT, Torvaldsen S, Moen A, et al. 
Global production capacity of seasonal 
and pandemic influenza vaccines in 
2019. Vaccine. 2021;39(3):512-520. doi: 
10.1016/j.vaccine.2020.12.018.
[18] Hoft DF, Brusic V, Sakala IG. 
Optimizing vaccine development. Cell 
Microbiol. 2011;13(7):934-942. doi: 
10.1111/j.1462-5822.2011.01609.x.
[19] Randolph HE, Barreiro LB. Herd 
Immunity: Understanding COVID-19. 
Immunity. 2020;52(5):737-741. doi: 
10.1016/j.immuni.2020.04.012.
[20] Fontanet A, Cauchemez S. COVID-
19 herd immunity: where are we? Nat 
Rev Immunol. 2020;20(10):583-584. 
doi: 10.1038/s41577-020-00451-5.
Fighting the COVID-19 Pandemic
16
[21] Metcalf CJE, Ferrari M, Graham AL, 
Grenfell BT. Understanding Herd 
Immunity. Trends Immunol. 
2015;36(12):753-755. doi: 10.1016/j.
it.2015.10.004.
[22] Pardi N, Hogan MJ, Porter FW, 
Weissman D. mRNA vaccines - a new 
era in vaccinology. Nat Rev Drug Discov. 
2018;17(4):261-279. doi: 10.1038/
nrd.2017.243.
[23] Chen WH, Strych U, Hotez PJ, 
Bottazzi ME. The SARS-CoV-2 Vaccine 
Pipeline: an Overview. Curr Trop Med 
Rep. 2020:1-4. doi: 10.1007/
s40475-020-00201-6.
[24] Al-Kassmy J, Pedersen J, 
Kobinger G. Vaccine Candidates against 
Coronavirus Infections. Where Does 
COVID-19 Stand? Viruses. 2020;12(8). 
doi: 10.3390/v12080861.
[25] Amanat F, Krammer F. SARS-CoV-2 
Vaccines: Status Report. Immunity. 
2020;52(4):583-589. doi: 10.1016/j.
immuni.2020.03.007.
[26] (CSSE) CfSSaE. Covid-19 
Dashboard. April 25 ed: Johns Hopkins 
University & Medicine; 2021.
